Mpox And Newfound ‘Punching Power’ Are Bringing Bavarian Nordic Closer To $1bn Target
Executive Summary
Bavarian Nordic managed to change its financial story in 2022 when its smallpox vaccine, Jynneos, became a critical tool in the global response to the mpox pandemic. CEO Paul Chaplin speaks to In Vivo about what this year holds in store.
You may also be interested in...
Bavarian Nordic Thinks Big With Emergent Travel Vaccines Buy
With the money coming in from monkeypox product Jynneos, the Danish firm has decided to pursue its goal of becoming one of the largest pure-play vaccine companies by acquiring jabs for cholera and typhoid from Emergent.
Preparing for COVID 2.0: Understanding Animal ‘Spillover’ And Addressing Excessive Nationalism
Former Merck executive Julie Gerberding, Biocon chief Kiran Mazumdar-Shaw, ModeX Therapeutics’ John Mascola, and NIH’s Larry Tabak discuss what it will take to better handle the next pandemic.
US Backs Oral COVID-19 Therapies And ‘Next Pandemic’ Drug Discovery With $3.2bn
Aiming to mimic public-private COVID-19 vaccine success, the US NIH will fund pandemic drug research, including taking candidates up to Phase II.